These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25143567)

  • 1. Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment.
    Guelfo JR; Macias J; Neukam K; Di Lello FA; Mira JA; Merchante N; Mancebo M; Nuñez-Torres R; Pineda JA; Real LM
    J Clin Microbiol; 2014 Nov; 52(11):4027-9. PubMed ID: 25143567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay.
    Avó AP; Agua-Doce I; Andrade A; Pádua E
    J Med Virol; 2013 May; 85(5):815-22. PubMed ID: 23508907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0.
    Larrat S; Poveda JD; Coudret C; Fusillier K; Magnat N; Signori-Schmuck A; Thibault V; Morand P
    J Clin Microbiol; 2013 Sep; 51(9):2815-21. PubMed ID: 23616453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.
    Némoz B; Roger L; Leroy V; Poveda JD; Morand P; Larrat S
    PLoS One; 2018; 13(3):e0194396. PubMed ID: 29566005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains.
    Trémeaux P; Caporossi A; Ramière C; Santoni E; Tarbouriech N; Thélu MA; Fusillier K; Geneletti L; François O; Leroy V; Burmeister WP; André P; Morand P; Larrat S
    Clin Microbiol Infect; 2016 May; 22(5):460.e1-460.e10. PubMed ID: 26827671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India.
    Verma V; Chakravarti A; Kar P
    Diagn Microbiol Infect Dis; 2008 Aug; 61(4):408-14. PubMed ID: 18455899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation of Hepatitis C Virus (HCV) Genotypes by "Reverse Hybridisation Strip Assay" and DNA Sequence Analysis Methods].
    Özmen P; Gökahmetoğlu S
    Mikrobiyol Bul; 2022 Jan; 56(1):68-80. PubMed ID: 35088961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.
    Kurbanov F; Tanaka Y; Matsuura K; Sugauchi F; Elkady A; Khan A; Hasegawa I; Ohno T; Tokuda H; Mizokami M
    J Infect Dis; 2010 Jun; 201(11):1663-71. PubMed ID: 20420509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study.
    Hino K; Yamaguchi Y; Fujiwara D; Katoh Y; Korenaga M; Okazaki M; Okuda M; Okita K
    J Viral Hepat; 2000 Jan; 7(1):36-42. PubMed ID: 10718941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals.
    Mourez T; Decroos A; Goria O; Montialoux H; De Oliveira F; Larrat S; Plantier JC; Riachi G
    J Med Virol; 2018 May; 90(5):994-997. PubMed ID: 29350410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
    Berenguer J; Gil-Martin Á; Jarrin I; Montes ML; Domínguez L; Aldámiz-Echevarría T; Téllez MJ; Santos I; Troya J; Losa JE; Serrano R; De Guzmán MT; Calvo MJ; González-García JJ;
    AIDS; 2019 Mar; 33(4):685-689. PubMed ID: 30829744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
    Hoffmann L; Ramos JA; Souza EV; Araújo Ramos AL; Villela-Nogueira CA; Urményi TP; Tanuri A; Rondinelli E; Silva R
    Virol J; 2013 Feb; 10():57. PubMed ID: 23409973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
    Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
    Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.
    Martinot-Peignoux M; Roudot-Thoraval F; Mendel I; Coste J; Izopet J; Duverlie G; Payan C; Pawlotsky JM; Defer C; Bogard M; Gerolami V; Halfon P; Buisson Y; Fouqueray B; Loiseau P; Lamoril J; Lefrere JJ; Marcellin P
    J Viral Hepat; 1999 Nov; 6(6):435-43. PubMed ID: 10607261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4.
    Zekri AR; El-Din HM; Bahnassy AA; El-Shehabi AM; El-Leethy H; Omar A; Khaled HM
    J Med Virol; 2005 Mar; 75(3):412-20. PubMed ID: 15648068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.